EYENOVIA INC (EYEN)

US30234E1047 - Common Stock

0.6309  +0.01 (+1.41%)

After market: 0.6624 +0.03 (+4.99%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

EYENOVIA INC

NASDAQ:EYEN (6/14/2024, 7:06:31 PM)

After market: 0.6624 +0.03 (+4.99%)

0.6309

+0.01 (+1.41%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-64.36%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap33.99M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

EYEN Daily chart

Company Profile

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 41 full-time employees. The company went IPO on 2018-01-25. The firm is developing the Optejet delivery system both for use in combination with its own drug-device therapeutics and for out-licensing for use in combination with therapeutics for additional indications. Its product candidates include MicroLine (for presbyopia), MicroPine (for progressive myopia) and Mydcombi (for mydriasis). MicroLine is its microdosed version of pilocarpine, a well-understood ophthalmic medication that can dose-dependently induce miosis, or a contraction of the pupil. MicroPine is a topical treatment for progressive myopia, a back-of-the-eye disease. MicroPine program involves the development of a micro-formulation of atropine ophthalmic solution for reduction of myopia progression in children. Mydcombi is a fixed combination micro-formulation product candidate for mydriasis (eye dilation). Its fixed combination product candidate has been developed to facilitate efficient pupil dilation.

Company Info

EYENOVIA INC

295 Madison Ave Ste 2400

New York City NEW YORK 10017

P: 18137669539

CEO: Tsontcho Ianchulev

Employees: 41

Website: https://eyenovia.com/

EYEN News

News Imagea month ago - InvestorPlaceEYEN Stock Earnings: Eyenovia Misses EPS, Misses Revenue for Q1 2024

EYEN stock results show that Eyenovia missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

News Imagea month ago - BusinessInsiderEYEN Stock Earnings: Eyenovia Misses EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eyenovia (NASDAQ:EYEN) just reported results for the first quarter of 2024.Eyen...

News Imagea month ago - Eyenovia, Inc.Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol

Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market,...

News Image2 months ago - Eyenovia, Inc.Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension

Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL...

News Image2 months ago - Eyenovia, Inc.Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities

Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024...

News Image2 months ago - Eyenovia, Inc.Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

Company to demonstrate Mydcombi™ and Avenova® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and...

EYEN Twits

Here you can normally see the latest stock twits on EYEN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example